Hutch News
Results per Page:
Antiviral immunity survives CD19-directed therapy
From the Hill and Turtle laboratories, Vaccine and Infections Disease Division and Clinical Research Division
Immunotherapy prevents relapse in small leukemia trial
Engineered T cells kept leukemia from returning in 12 high-risk patients
“Exciting” but early results in trial of immunotherapy for myeloma
Cancer cells disappeared rapidly in patients with high-risk, treatment-resistant disease
Immunotherapy strategy for ovarian cancer aims to rewire a ‘kill switch’ to ramp-up signal
T cells bearing a new engineered protein boost immunotherapy’s effectiveness in laboratory models of AML, ovarian, pancreatic cancers
First systematic study of infections after CAR T-cell therapy
“Benchmark” research could help reduce complications of emerging immunotherapy
Forum at Fred Hutch focuses on the hottest developments in cancer immunotherapy
Immune-based treatments move from the fringes to the spotlight
5 researchers receive awards to explore immunotherapy single-cell RNA sequencing
Projects accelerate Hutch position as early adopter of scRNA-seq technology
A Q&A with immunotherapy researcher Dr. Rachel Perret
As part of a world-class immunotherapy research team, Perret is working her ‘dream job’ — trying to bring T-cell therapy to all who need it
6 questions in cancer immunotherapy
From cancer vaccines to engineered T cells, experts weigh in on the big unknowns
NCI awards $11.5 million to Fred Hutchinson Cancer Research Center to lead breast cancer research consortium
Projects include developing targeted therapies to treat drug-resistant tumors